BioSpace

This week Lori, Greg and Tyler discuss drug pricing reforms. CMS sent offers to manufacturers of the 10 drugs that have been selected for Medicare price negotiations. What's the best way forward that benefits patients while still supporting the innovation that makes these drugs possible? How will the election impact negotiations?

Also discussed earnings including Novo Nordisk, who beat analyst expectations largely due to sales of Ozempic and Wegovy, AbbVie, Merck, and GSK.

Almost 30,000 patients have now been treated with CAR-T cell therapies since it was the first approval in 2017. In November 2023, the FDA launched a probe into malignancies caused by CAR T therapies, and just last week the agency called for a class-wide box warning on all commercial CAR-T therapies with ongoing investigations into cases of secondary malignancies. How do we approach this balancing act of treatment and side effects?

Also this week: IPOs march on with ArriVent, CG Oncology, Alto Neuroscience, Fractyl Health; and what's happening re: Congressional Budget Office, Centers for Medicare & Medicaid Services and drug pricing.

Join BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen as they discuss.

Following a challenging year of layoffs and limited funding, Chantal Dresner, VP of Marketing at BioSpace, discusses the findings of our most recent Employment Outlook Report including unemployment, anticipated job search activity, hiring trends and current workforce sentiment.

The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announcements.

Lori, Greg and Tyler also discuss gene therapy pricing including Vertex/CRISPR's Casgevy.

The team comes together to discuss the dominant themes of what was an incredibly busy week of events in San Francisco.

There was an air of hope and optimism concerning biopharma funding - but will it last?

Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.

We're still in San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day three: disruptive AI ⁠is still a hot topic including generative AI; M&A and VC funding; and general whiffs of cautious optimism.

Join Lori, Greg and Tyler as they discuss what's been top of mind today.

You can ⁠⁠⁠follow our coverage⁠⁠⁠ as our team adds updates throughout the day.

Once again we're recording from San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day two: AI, cell and gene therapy innovation and pricing, and the risks of CAR T cell therapy.

Join Lori, Greg and Tyler as they discuss what's been top of mind.

You can ⁠⁠follow our coverage⁠⁠ as our team adds updates throughout the day.

Join us tomorrow for Day 3 highlights!

Hello from San Francisco! BioSpace is reporting from #JPM2024 bringing you key takeaways and highlights from day one.

Join Lori, Greg and Tyler as they discuss what's moving and shaking.

You can ⁠follow our coverage⁠ as our team adds updates throughout the day.

Get Greg's take on ⁠what this year might hold⁠ in store and how the Biden administration's policies may ⁠play a role in discussions⁠.

Join us tomorrow for Day 2 highlights!

The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that investors are excited before taking the plunge. Given the current economic environment that is causing challenges in biopharma, how should companies be approaching funding in 2024?

Listen to this discussion on different kinds of funding options available, how companies can optimize their chances to secure funding and how they should be assessing VCs in addition to alternative partners – particularly if your company will be seeking funding at JPM next week. Our host and guests also discuss current challenges, how to weather adversity, and what investment trends are anticipated for next year.

You can also watch the roundtable on BioSpace.

Host 

⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace  

Guests

Jeff Burton, CFO, Halia Therapeutics

Karen Harris, CFO and Head of Mission-Related Investing, The Alzheimer's Drug Foundation

Rob Williamson, President and COO, Triumvira Immunologics

Welcome to 2024! This week we're discussing BioSpace's tenth annual list of the hottest new life sciences companies in the U.S. NextGen Class of 2024⁠ includes organizations that launched between September 2022 and September 2023 with a Series A funding. 

BioSpace's Greg Slabodkin, Heather McKenzie and Tyler Patchen discuss.